Gery Sigal, Tanosaki Sakae, Bose Shikha, Bose Namrata, Vadgama Jay, Koeffler H Phillip
Division of Hematology/Oncology, Cedars-Sinai Medical Center, University of California at Los Angeles School of Medicine, USA.
Clin Cancer Res. 2005 May 1;11(9):3184-90. doi: 10.1158/1078-0432.CCR-04-2625.
CCAAT/enhancer binding proteins (C/EBP) are a family of transcription factors that regulate proliferation and differentiation in a variety of tissues. The purpose of this study was to explore the possibility that C/EBPalpha is involved in breast cancer.
We quantified C/EBPalpha mRNA expression levels in 24 primary breast tumors, 16 normal breast samples, and 8 breast cancer cell lines using quantitative real-time reverse transcription-PCR assay. C/EBPalpha protein levels were further determined by immunohistochemical analysis. To examine the consequence of C/EPBalpha expression in breast cancer, we stably transfected an inducible C/EPBalpha expression vector into three breast cancer cell lines.
Low expression of C/EBPalpha mRNA was found in 83% of primary breast cancer samples. Immunohistochemical study further showed either a markedly reduced or undetectable expression of C/EBPalpha protein in 30% of breast cancer specimens. The other 70% of breast cancers had C/EBPalpha expression in both the cytoplasm and nucleus; in control, C/EBPalpha was localized to the nucleus in the normal ductal cells. C/EBPalpha expression was associated with estrogen- and progesterone receptor-negative status. Induction of C/EBPalpha expression in these cell lines resulted in growth inhibition accompanied by G0-G1 cell cycle arrest and reduced anchorage-independent cell growth. C/EBPalpha expression was associated with down-regulation of c-myc and up-regulation of p21, PPARgamma, and the breast epithelial differentiation marker, maspin.
These results suggest that reduced expression of C/EBPalpha may play a role in the development and/or progression of breast cancer.
CCAAT/增强子结合蛋白(C/EBP)是一类转录因子家族,可调节多种组织中的增殖和分化。本研究的目的是探讨C/EBPα参与乳腺癌发生的可能性。
我们采用定量实时逆转录-PCR分析法,对24例原发性乳腺肿瘤、16例正常乳腺样本和8种乳腺癌细胞系中的C/EBPα mRNA表达水平进行了定量分析。通过免疫组织化学分析进一步测定C/EBPα蛋白水平。为了研究C/EPBα在乳腺癌中表达的后果,我们将一种可诱导的C/EPBα表达载体稳定转染至三种乳腺癌细胞系中。
在83%的原发性乳腺癌样本中发现C/EBPα mRNA表达水平较低。免疫组织化学研究进一步显示,在30%的乳腺癌标本中,C/EBPα蛋白表达明显降低或无法检测到。其他70%的乳腺癌在细胞质和细胞核中均有C/EBPα表达;而在正常导管细胞中,C/EBPα定位于细胞核。C/EBPα表达与雌激素和孕激素受体阴性状态相关。在这些细胞系中诱导C/EBPα表达导致生长抑制,同时伴有G0-G1细胞周期停滞和非贴壁依赖性细胞生长减少。C/EBPα表达与c-myc的下调以及p21、PPARγ和乳腺上皮分化标志物maspin的上调相关。
这些结果表明,C/EBPα表达降低可能在乳腺癌的发生和/或进展中起作用。